Bausch Health Companies (BHC) Other Non-Current Liabilities (2009 - 2026)
Bausch Health Companies (BHC) posted Other Non-Current Liabilities of $733.0 million for Q2 2026, down 3.93% sequentially from $763.0 million in Q1 2026, and down 16.42% YoY from $877.0 million in Q2 2025.
Bausch Health Companies (BHC) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Bausch Health Companies has reported Other Non-Current Liabilities for 18 years, with the latest figure at $733.0 million in Q2 2026.
- Quarterly Other Non-Current Liabilities fell 16.42% year-over-year to $733.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $733.0 million (down 16.42% YoY) and the FY2025 annual result came in at $793.0 million, up 11.22% from the prior year.
- Other Non-Current Liabilities slipped to $733.0 million in Q2 2026 per BHC's latest filing, from $763.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $877.0 million in Q2 2025 and troughed at $524.0 million in Q2 2022.
- A 5-year average of $733.3 million and a median of $745.5 million in 2023 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities plunged 46.26% in 2022, then soared 42.18% in 2023.
- Over 5 years, Other Non-Current Liabilities stood at $741.0 million in 2022, then increased by 4.72% to $776.0 million in 2023, then declined by 8.12% to $713.0 million in 2024, then gained by 11.22% to $793.0 million in 2025, then dropped by 7.57% to $733.0 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $733.0 million, $763.0 million, and $793.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Bausch Health Companies | 2.42 Bn | 586.38 Mn | 2.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 733.00 Mn |
| Mar 31, 2026 | 763.00 Mn |
| Dec 31, 2025 | 793.00 Mn |
| Sep 30, 2025 | 843.00 Mn |
| Jun 30, 2025 | 877.00 Mn |
| Mar 31, 2025 | 761.00 Mn |
| Dec 31, 2024 | 713.00 Mn |
| Sep 30, 2024 | 805.00 Mn |
| Jun 30, 2024 | 745.00 Mn |
| Mar 31, 2024 | 751.00 Mn |
| Dec 31, 2023 | 776.00 Mn |
| Sep 30, 2023 | 721.00 Mn |
| Jun 30, 2023 | 745.00 Mn |
| Mar 31, 2023 | 746.00 Mn |
| Dec 31, 2022 | 741.00 Mn |
| Sep 30, 2022 | 619.00 Mn |
| Jun 30, 2022 | 524.00 Mn |
| Mar 31, 2022 | 544.00 Mn |
| Dec 31, 2021 | 653.00 Mn |
| Sep 30, 2021 | 872.00 Mn |